PMID- 33995528
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2021
DP  - 2021
TI  - Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of 
      Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A 
      Retrospective Study.
PG  - 5524685
LID - 10.1155/2021/5524685 [doi]
LID - 5524685
AB  - OBJECTIVE: Anti-PD-1 has dramatically improved the survival of patients with 
      advanced melanoma. However, there is a lack of data on maintenance of the 
      response after treatment discontinuation. We aimed to evaluate the 
      progression-free survival (PFS) of patients with metastatic melanoma after 
      anti-PD-1 interruption for objective response (OR) or limiting toxicity during 
      clinical trials. METHODS: All patients with advanced melanoma who stopped 
      single-agent anti-PD-1 antibodies for objective response or toxicity were 
      included between April 2014 and January 2019 in our institution (data cut-off, 
      September 10th, 2019). Clinical and biological factors associated with relapse 
      were studied. RESULTS: The median follow-up after introduction of treatment was 
      36.5 months [4.6-62.4], and the median follow-up after discontinuation of 
      treatment was 15.7 months (2.5-45.1). Out of 65 patients, 28 patients stopped 
      immunotherapy for limiting adverse effects (AEs) (43.1%), 25 for complete 
      response (CR) (38.4%), and 12 for partial response (PR) or long-term stable 
      disease (SD) (18.5%). Twelve patients relapsed (18.5%) after a median time of 9 
      months [1.9-40.9 months]. Seven relapsed after discontinuation for AEs, 3 after 
      discontinuation for CR, and 2 after discontinuation for PR/SD. The median PFS 
      after therapy discontinuation was not reached. No statistical association was 
      found between recurrence and age, sex, increased LDH, BRAF status, presence of 
      brain metastases, previous treatments, radiotherapy, or time on anti-PD-1 
      treatment. CONCLUSION: This cohort shows a global recurrence rate of 18.5% and 
      confirms a long-lasting response after anti-PD-1 cessation regardless of the 
      cause of discontinuation.
CI  - Copyright (c) 2021 Julie Valentin et al.
FAU - Valentin, Julie
AU  - Valentin J
AUID- ORCID: 0000-0002-7437-2662
AD  - Department of Dermatology, Hospital Saint Andre, University Hospital of Bordeaux, 
      Bordeaux, France.
FAU - Ferte, Thomas
AU  - Ferte T
AD  - Bordeaux Hospital University Center, Pole de Sante Publique, Service 
      D'information Medicale, Unite Informatique et Archivistique Medicales, F-33000 
      Bordeaux, France.
FAU - Dorizy-Vuong, Valerie
AU  - Dorizy-Vuong V
AD  - Department of Dermatology, Hospital Saint Andre, University Hospital of Bordeaux, 
      Bordeaux, France.
FAU - Dousset, Lea
AU  - Dousset L
AD  - Department of Dermatology, Hospital Saint Andre, University Hospital of Bordeaux, 
      Bordeaux, France.
AD  - Universite de Bordeaux, INSERM U1035, F-33076 Bordeaux, France.
FAU - Prey, Sorilla
AU  - Prey S
AD  - Department of Dermatology, Hospital Saint Andre, University Hospital of Bordeaux, 
      Bordeaux, France.
AD  - Universite de Bordeaux, INSERM U1035, F-33076 Bordeaux, France.
FAU - Dutriaux, Caroline
AU  - Dutriaux C
AD  - Department of Dermatology, Hospital Saint Andre, University Hospital of Bordeaux, 
      Bordeaux, France.
AD  - Universite de Bordeaux, INSERM U1035, F-33076 Bordeaux, France.
FAU - Pham-Ledard, Anne
AU  - Pham-Ledard A
AD  - Department of Dermatology, Hospital Saint Andre, University Hospital of Bordeaux, 
      Bordeaux, France.
AD  - INSERM U1053, Bordeaux Research in Translational Oncology, Team 3 Oncogenesis of 
      Cutaneous Lymphomas, Universite de Bordeaux, Bordeaux, France.
FAU - Beylot-Barry, Marie
AU  - Beylot-Barry M
AD  - Department of Dermatology, Hospital Saint Andre, University Hospital of Bordeaux, 
      Bordeaux, France.
AD  - INSERM U1053, Bordeaux Research in Translational Oncology, Team 3 Oncogenesis of 
      Cutaneous Lymphomas, Universite de Bordeaux, Bordeaux, France.
FAU - Gerard, Emilie
AU  - Gerard E
AUID- ORCID: 0000-0003-1765-461X
AD  - Department of Dermatology, Hospital Saint Andre, University Hospital of Bordeaux, 
      Bordeaux, France.
LA  - eng
PT  - Journal Article
DEP - 20210427
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC8096591
COIS- Consulting and advisory role for Bristol-Myers Squibb (APL, CD, MBB); travelling, 
      expenses and accommodation (APL, CD, MBB, SP, EG). JV, TF, VDV, and LD have no 
      conflicts of interest.
EDAT- 2021/05/18 06:00
MHDA- 2021/05/18 06:01
PMCR- 2021/04/27
CRDT- 2021/05/17 06:05
PHST- 2021/02/07 00:00 [received]
PHST- 2021/03/25 00:00 [revised]
PHST- 2021/04/09 00:00 [accepted]
PHST- 2021/05/17 06:05 [entrez]
PHST- 2021/05/18 06:00 [pubmed]
PHST- 2021/05/18 06:01 [medline]
PHST- 2021/04/27 00:00 [pmc-release]
AID - 10.1155/2021/5524685 [doi]
PST - epublish
SO  - J Oncol. 2021 Apr 27;2021:5524685. doi: 10.1155/2021/5524685. eCollection 2021.